Chronic administration of apple polyphenols ameliorates hyperglycaemia in high-normal and borderline subjects: A randomised, placebo-controlled trial

•12weeks apple polyphenol administration were assessed on high-normal and borderline types in a double-blinded, placebo-controlled clinical trial.•Apple polyphenol ameliorated postprandial hyperglycaemia in high-normal and borderline types. We previously reported that apple polyphenols (AP) and thei...

Full description

Saved in:
Bibliographic Details
Published inDiabetes research and clinical practice Vol. 129; pp. 43 - 51
Main Authors Shoji, Toshihiko, Yamada, Mitsuhiro, Miura, Tomisato, Nagashima, Kazuaki, Ogura, Kasane, Inagaki, Nobuya, Maeda-Yamamoto, Mari
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.07.2017
Subjects
ALP
ALT
IFG
LPS
LDH
BMI
AST
AP
TC
CVD
TG
APC
IGT
NGT
FPG
Online AccessGet full text

Cover

Loading…
More Information
Summary:•12weeks apple polyphenol administration were assessed on high-normal and borderline types in a double-blinded, placebo-controlled clinical trial.•Apple polyphenol ameliorated postprandial hyperglycaemia in high-normal and borderline types. We previously reported that apple polyphenols (AP) and their major active components, procyanidins, had beneficial effects on glucose homeostasis and diabetes in diabetic ob/ob mice. The present study was performed to evaluate the effects of chronic AP administration on glucose tolerance in high-normal and borderline human subjects. Subjects (n=65) with a fasting plasma glucose (FPG) level of 100–125mg/dL determined during a recent health check-up were randomised to receive tablets containing AP (600mg/day) or placebo tablets for 12weeks in a double-blinded, placebo-controlled clinical trial. The primary outcome was insulin resistance, assessed using a 75g oral glucose tolerance test (OGTT). The 12-week chronic administration of AP significantly reduced the increase in glucose at 30-min post-75g OGTT (OGTT30-min glucose) value, compared to the placebo regimen. Furthermore, in a subgroup of the high-normal (FPG value, 100–109mg/dL; 2-h post-75g OGTT glucose (OGTT2-h glucose) value, <140mg/dL) and borderline (FPG value, 110–125mg/dL; OGTT2-h glucose value, <140mg/dL and FPG value, <126mg/dL; OGTT2-h glucose value, 140–199mg/dL) subjects, OGTT30-min glucose value in the AP group (164.0±7.4mg/dL) was significantly lower than that of the placebo group (194.7±10.4mg/dL, p<0.05). No significant changes in the other lipid parameters and cytokine levels were observed. Chronic AP administration significantly improved impaired glucose tolerance in high-normal and borderline subjects. Larger and/or longer-term scale human studies are required to confirm the potential glucose homeostasis of AP.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0168-8227
1872-8227
1872-8227
DOI:10.1016/j.diabres.2017.03.028